Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Non-Hodgkin's Lymphoma
DRUG: hA20-humanized anti-CD20 antibody
Safety and tolerance of different dose levels, 12 weeks
Lack of immunogenicity, 8 and 12 weeks|Pharmacodynamics, over 12 weeks|Pharmacokinetics, over 12 weeks|Efficacy, 4, 8 and 12 wks, every 3 months
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.